← All trials
NCT05551832
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 10, 2022
- Primary completion
- Oct 1, 2023
- Completion date
- May 30, 2025
- First posted
- Sep 23, 2022
- Last posted
- Oct 25, 2022
- Enrollment
- 360
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Yonsei UniversityLead sponsor
- Yonsei UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.